Proactive Investors - Run By Investors For Investors

Immuron enrols first patient in paediatric fatty liver trial in the U.S.

Pediatric NAFLD is a progressive form of liver disease.
Immuron enrols first patient in paediatric fatty liver trial in the U.S.
The trial is designed to assess Immuron’s unique treatment

Immuron (ASX:IMC) has enrolled the first patient for its paediatric NAFLD (non-alcoholic fatty liver disease) Phase II trial conducted by Emory University in Georgia, U.S.

This Phase II, double blind, randomized study is designed to assess the safety and efficacy of Immuron’s IMM-124E for the treatment of paediatric NAFLD.

Paediatric NAFLD is a progressive form of liver disease associated with excessive fat storage in the liver together with inflammation, which can then lead to liver fibrosis and cirrhosis.

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is a unique treatment option compared to other leading investigational agents.

The principal objective of this study is to evaluate whether 12 weeks of IMM-124E treatment in children with confirmed NALFD will decrease serum ALT.

The study aims to enrol 40 paediatric patients.

Paediatric NAFLD is believed to affect up to 5% - 10% of the U.S. paediatric population.

A U.S. landmark study that examined the incidence of the disease in 742 children found that 17.3% of children aged 15 to 19 years had NAFLD.

There are currently no treatments approved for paediatric NAFLD.

Immuron’s share price has increased about 11% since the start of 2017, last trading at $0.30.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

seeds in a bowl
March 08 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use